Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Advanced analytical methods integrating clinical trial and real-world data address key evidence gaps in rare, difficult-to-treat blood cancers Across both studies, mogamulizumab was associated with...
-
Clinically meaningful improvements in skin symptoms reported as early as week 4 and sustained over the 48-week study period Data presented at the 6th World Congress of Cutaneous Lymphomas meeting in...
-
PRINCETON, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co. Ltd., and The XLH Network, a non-profit patient advocacy organization, today...
-
PRINCETON, N.J., June 10, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co. Ltd (TSE: 4151), today announced new data further defining the potential of...
-
Expanded dosing options support individualized treatment for adults with XLH PRINCETON, N.J., May 14, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co. Ltd.,...
-
Public drug coverage now provides eligible adults access to CRYSVITA, the only approved treatment for X-linked hypophosphatemia (XLH), a lifelong progressive disease TORONTO, May 06, 2026 (GLOBE...
-
La couverture publique des médicaments permet maintenant aux adultes admissibles d’accéder à CRYSVITA, le seul traitement approuvé pour l’hypophosphatémie liée au chromosome X (XLH), une maladie...
-
TOKYO and SAN DIEGO, April 24, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin Co., Ltd. (TSE: 4151, “Kyowa Kirin”) and Kura Oncology, Inc. (Nasdaq: KURA, “Kura”) today announced the first patient has been...
-
TOKYO AND PRINCETON, Japan and the U.S., March 03, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, today announced the...
-
Kyowa Kirin menegaskan komitmen syarikat terhadap pembangunan Rocatinlimab sebagai aset berbeza yang berpotensi mengubah kehidupan dengan prospek pasaran yang signifikan.Pendekatan inovatif...